Zobrazeno 1 - 5
of 5
pro vyhledávání: '"J L, Vidal Pérez"'
Autor:
M. A. García-Viejo, I. Suárez-García, A. Noguerado-Asensio, J. L. Vidal-Pérez, A. Rodríguez-Blanco, O. López, M. J. Jaras-Hernández
Publikováno v:
European Journal of Clinical Microbiology & Infectious Diseases. 28:325-330
The setting for this retrospective cohort study was a specialised tuberculosis unit in Madrid, Spain. The objective was to describe the risk factors for multidrug-resistant tuberculosis (MDR-TB). The medical records of all patients admitted to the un
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24cf38a045b340efeb70102958c893ec
https://doi.org/10.1007/s10096-008-0627-y
https://doi.org/10.1007/s10096-008-0627-y
Autor:
Y. A. Noguerado Asensio, J. L. Vidal Pérez, A. Rodríguez Blanco, B. Moreno González, Ricardo Rodríguez Barrientos
Publikováno v:
Revista Clínica Española. 205:430-432
Rifampicin is an essential drug in the present treatment of tuberculosis. On some occasions, it cannot be used due to severe adverse effects. Rifabutin is a drug of the same family, with a similar activity and difference adverse effects. This study d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c9c608ca073a4f400ff6678eeadefa65
https://doi.org/10.1157/13079071
https://doi.org/10.1157/13079071
Autor:
L, Soler Rangel, M A, García Viejo, M J, Jaras Hernández, J L, Vidal Pérez, O, López Mesonero, A, Noguerado Asensio
Publikováno v:
Revista clinica espanola. 209(10)
In Spain there is a high prevalence of tuberculosis (TB). The aim of this study is to describe population attended in an Isolation Unit, analysing the changes that have occurred in 10 years, the impact of immigration and factors that may condition th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4173e220c11571d4fb66a896e192a143
https://pubmed.ncbi.nlm.nih.gov/19889316
https://pubmed.ncbi.nlm.nih.gov/19889316
Autor:
B, Moreno González, A, Rodríguez Blanco, R, Rodríguez Barrientos, J L, Vidal Pérez, A, Noguerado Asensio
Publikováno v:
Revista clinica espanola. 205(9)
Rifampicin is an essential drug in the present treatment of tuberculosis. On some occasions, it cannot be used due to severe adverse effects. Rifabutin is a drug of the same family, with a similar activity and difference adverse effects. This study d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7bd31000a3ebcd6823761899e2c6667a
https://pubmed.ncbi.nlm.nih.gov/16194477
https://pubmed.ncbi.nlm.nih.gov/16194477
Publikováno v:
Anales de Medicina Interna v.21 n.10 2004
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname
Anales de Medicina Interna, Volume: 21, Issue: 10, Pages: 61-62, Published: OCT 2004
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname
Anales de Medicina Interna, Volume: 21, Issue: 10, Pages: 61-62, Published: OCT 2004
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4787dabe5c02b54d4e3061bb532f7753
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0212-71992004001000012
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0212-71992004001000012
